Clinical trials: in Honduras
Scabies
A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies
To determine and compare the safety and efficacy of permethrin foam 4% and permethrin foam 5% with that of vehicle in subjects with scabies.
- Trial name
- NCT02094716
- Testing
- Permethrin Foam 4%, Permethrin Foam 5%, Vehicle Foam
- Where
- 9 sites in United States, Dominican Republic and 2 more
- Volunteers
- 130 people
- Sponsor
- Mylan Inc.
Respiratory Syncytial Virus
A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
The purpose of this study is to assess the incidence and associated healthcare utilization of RSV-associated, suspected LRTI in a general population of infants from birth up to 2 years of age, and also to assess the accuracy of a…
- Trial name
- NCT01995175
- Testing
- Nasal swab sampling, Blood sampling, Diary cards
- Where
- 23 sites in United States, Argentina and 6 more
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
The aim of the study was to assess and describe the booster effect of a CYD dengue vaccine dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule.
- Trial name
- NCT02623725
- Testing
- CYD Dengue Vaccine (5-dose formulation)
- Where
- 5 sites in Brazil, Colombia and 3 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
Primary objectives: To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine.
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Dengue Virus, Dengue Fever
- Trial name
- NCT00993447
- Testing
- CYD Dengue Vaccine, Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
- Where
- 4 sites in Colombia, Honduras and 2 more
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue
- Trial name
- NCT01374516
- Testing
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Where
- 22 sites in Brazil, Colombia and 3 more
- Volunteers
- 20,869 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Atopic Dermatitis
Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
To establish the bioequivalence between test drug, Pimecrolimus Cream, 1% with that of reference listed drug, Elidel® (pimecrolimus) Cream 1%, in the treatment of mild to moderate Atopic Dermatitis.
- Trial name
- NCT03107611
- Testing
- Pimecrolimus Cream, 1%
- Where
- 27 sites in United States, Dominican Republic and 1 more
- Volunteers
- 654 people
- Sponsor
- Mylan Inc.
COVID-19
Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras
This is a single-arm, open-label, phase II clinical study to evaluate the safety and efficacy of thymic peptides in the treatment of hospitalized COVID-19 patients in Honduras.
- Trial name
- NCT04771013
- Testing
- Thymic peptides
- Where
- Honduras
- Volunteers
- 22 people
- Sponsor
- Universidad Católica de Honduras
Influenza
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age
The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new influenza vaccine GSK2282512A (FLU-Q-QIV) and compare its activity to the marketed vaccine Fluarix® (TIV) in young children 6 to…
- Trial name
- NCT01711736
- Testing
- Quadrivalent influenza GSK2282512A vaccine, Fluarix
- Where
- 8 sites in Canada, Dominican Republic and 1 more
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cachexia
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.
- Trial name
- NCT00698828
- Testing
- SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 227 people
- Sponsor
- Daiichi Sankyo
Trichuris Infection, Helminthiasis
Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
There are four species of intestinal worms collectively known as soil-transmitted helminthiasis (STH): Ancylostoma duodenale and Necator americanus (hookworms), Ascaris lumbricoides (roundworms), and Trichuris trichiura…
- Trial name
- HI4T (NCT04041453)
- Testing
- Ivermectin, Albendazole
- Where
- 2 sites in Argentina, Honduras
- Volunteers
- 176 people
- Sponsor
- Alejandro Krolewiecki
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the 580299 HPV vaccine up to 10 years…
- Trial name
- NCT00877877
- Testing
- Blood sampling
- Where
- 26 sites in Colombia, Germany and 3 more
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tinea Corporis
Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
The objective of this study was to evaluate the safety, efficacy, and pharmacokinetics of luliconazole cream 1% when applied topically for 7 days in pediatric participants 2 years to 17 years of age (inclusive) with tinea…
- Trial name
- NCT02767947
- Testing
- Luliconazole Cream 1%, Vehicle Cream
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 75 people
- Sponsor
- Bausch Health Americas, Inc.
Tinea Pedis, Tinea Cruris
Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
The objective of this study is to evaluate the pharmacokinetics of luliconazole cream 1%, as measured by circulating plasma levels of luliconazole, when maximal quantity of luliconazole cream 1% is applied to participants of 12…
- Trial name
- NCT02767271
- Testing
- Luliconazole Cream 1%
- Where
- 2 sites in Dominican Republic, Honduras
- Volunteers
- 30 people
- Sponsor
- Bausch Health Americas, Inc.
Atopic Dermatitis
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.
- Trial name
- NCT02945657
- Testing
- MM36 topical ointment, 1%
- Where
- 12 sites in United States, Honduras and 1 more
- Volunteers
- 32 people
- Sponsor
- Medimetriks Pharmaceuticals, Inc
Influenza
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age.
- Trial name
- NCT01439360
- Testing
- Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A, Havrix Junior, Prevenar 13
- Where
- 103 sites in Bangladesh, Belgium and 11 more
- Volunteers
- 12,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children
This study is designed to test the efficacy of an investigational influenza vaccine, in children compared to Havrix®, a licensed Hepatitis A virus vaccine.
- Trial name
- NCT01218308
- Testing
- FluLaval® Quadrivalent, Havrix™
- Where
- 12 sites in Bangladesh, Dominican Republic and 6 more
- Volunteers
- 5,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
To demonstrate the free combination of budesonide and indacaterol is as efficacious as fluticasone and salmeterol in patients with COPD
- Trial name
- COMBINE (NCT02055352)
- Testing
- Budesonide, Fluticasone, Indacaterol
- Where
- 25 sites in Argentina, Brazil and 6 more
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Onychomycosis
Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.
Onychomycosis is a common condition accounting for approximately half of all nail disorders. It is most commonly caused by dermatophytes.
- Trial name
- NCT00356915
- Testing
- Itraconazole 100mg capsules, Itraconazole 200mg tablets
- Where
- 68 sites in United States, Canada and 5 more
- Volunteers
- 1,381 people
- Sponsor
- Stiefel, a GSK Company
Tinea Pedis, Tinea Cruris
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch.
- Trial name
- NCT01712360
- Testing
- NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult)
- Where
- 4 sites in United States, Dominican Republic and 1 more
- Volunteers
- 56 people
- Sponsor
- Merz North America, Inc.
Pain
Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic
This is a multicenter, randomized, double blind, double dummy, comparative, active-controlled trial designed to assess the analgesic activity and safety of intravenous doses of parecoxib 40 mg relative to intravenous doses of…
- Trial name
- NAP (NCT00553605)
- Testing
- Ketoprofen 100mg, Parecoxib 40mg
- Where
- 17 sites in Brazil, Chile and 4 more
- Volunteers
- 340 people
- Sponsor
- Pfizer